ALLIANCES AND COLLABORATIONS (AstraZeneca) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Alliances and Collaborations Statement [Line Items]
Net product sales	$ 3,059	$ 2,807
Alliance and other revenues	982	1,004
Total revenues	4,041	3,811
Cost of products sold - amortization of deferred income	(847)	(968)
Provision for restructuring	12	21
Gain on sale of business	154	259
Deferred income - Cash Flow information	334	327
Business divestitures and other proceeds	203	3,055
Deferred income	2,156		1,937
Earned royalties included in other income	161	108
AstraZeneca [Member]
Alliances and Collaborations Statement [Line Items]
Net product sales		160
Alliance and other revenues	54	19
Total revenues	54	179
Profit sharing - Cost of products sold		76
Payments to/(from) alliance partners - Cost of products sold		(9)
Payments to/(from) alliance partners - Marketing, selling and administrative		(11)
Payments to/(from) alliance partners - Advertising and product promotion		(3)
Payments to/(from) alliance partners - Research and development		(7)
Provision for restructuring		(2)
Royalties	(81)	(48)
Transitional services	(3)	(31)
Gain on sale of business	(5)	(259)
Deferred income - Cash Flow information	1	275
Business divestitures and other proceeds	12	3,055
AstraZeneca [Member] | Amortization Income Expense [Member]
Alliances and Collaborations Statement [Line Items]
Amortization of deferred income	(24)	(13)
AstraZeneca [Member] | Assets Not Yet Transferred to Alliance Partner [Member]
Alliances and Collaborations Statement [Line Items]
Deferred income	180		176
AstraZeneca [Member] | Services Not Yet Performed For Alliance Partner [Member]
Alliances and Collaborations Statement [Line Items]
Deferred income	$ 207		$ 226